REAL-TIME BEDSIDE MONITORING OF BLOOD PROPOFOL CONCENTRATIONS:

REAL-TIME BEDSIDE MONITORING OF BLOOD PROPOFOL CONCENTRATIONS: Comparison between propofol 2% and propofol 1%

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON25330

Enrollment

Registered

2013-05-15

Start date

2013-05-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood propofol concentrations Intrancranial neurosurgical intervention ear surgery Nociception Influence of opioid supplementation

Interventions

Part I: A comparison of blood propofol concentrations during a TCI administration of a 1% or 2% formulation of propofol during intracranial neurosurgery/thyroid surgery/ear surgery I.V. line for prop

Eligibility

Inclusion criteria

Inclusion criteria: Male and female non-pregnant patients scheduled for elective intracranial surgery, ear surgery or thyroid surgery with a minimal duration of at least 3 hours. ASA Physical status I or II Age between 18-75 years

Exclusion criteria

Exclusion criteria: Serious impairment of respiratory, cardiovascular, hepatic, renal, haematopoetic or endocrine function. Known allergy to propofol or constituents (Soya-bean-eggs). Previous adverse experience of general anaesthesia. Pregnancy. More than 50% under or above ideal weight. History of opioid drug abuse or alcohol addiction. Concurrent use of beta-blockers

Design outcomes

Primary

Measure	Time frame
The aim of this study will be to prospectively test the validity of the Pelorus rapid propofol measurement system(Spere Medical) during TIVA anesthesia.	—

Secondary

Measure	Time frame
• the pharmacokinetic interaction between propofol and sufentanil • gender differences in pharmacokinetics and dynamics of propofol • the influence of age on pharmacokinetics of propofol Determine whether the blood propofol concentrations are influenced by concomitant administration of sufentanil or remifentanil	—

Contacts

Public ContactVeerle Mossevelde, van

Laarbeeklaan 101

veerle.vanmossevelde@uzbrussel.be+32 (0)2 4763134

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)